cover
Contact Name
Rachmat Hidayat
Contact Email
dr.rachmat.hidayat@gmail.com
Phone
+6281949581088
Journal Mail Official
editor.bioscmed@gmail.com
Editorial Address
Jl. Sirna Raga no 99, 8 Ilir, Ilir Timur 3, Palembang
Location
Kota palembang,
Sumatera selatan
INDONESIA
Bioscientia Medicina : Journal of Biomedicine and Translational Research
Published by HM Publisher
ISSN : -     EISSN : 25980580     DOI : https://doi.org/10.37275/bsm
Core Subject : Health, Science,
This journal welcomes the submission of articles that offering a sensible transfer of basic research to applied clinical medicine. BioScientia Medicina covers the latest developments in various fields of biomedicine with special attention to : 1.Rhemumatology 2.Molecular aspect of Indonesia Traditional Herb 3.Cardiology and Cardiovascular diseases 4.Genetics 5.Immunology 6.Environmental health 7.Toxicology 8. Neurology 9. Pharmacology 10. Oncology 11. Other multidisciplinary studies related medicine. The views of experts on current advances in nanotechnology and molecular/cell biology will be also considered for publication as long as they have a direct clinical impact on human health.
Articles 1,165 Documents
Massive Hemoptysis: A Meta-Analysis of Urgent Interventional Approaches Bambang Rojullun Taufik; Russilawati; Dewi Wahyu Fitrina
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1272

Abstract

Background: Massive hemoptysis is a life-threatening medical emergency requiring immediate intervention. This meta-analysis evaluated the efficacy and safety of urgent interventional approaches for managing massive hemoptysis. Methods: A systematic search of electronic databases (PubMed, Embase, Scopus) was conducted from January 2013 to February 2024. Studies comparing different urgent interventional approaches (bronchial artery embolization [BAE], bronchoscopic interventions, surgery) in adults with massive hemoptysis were included. The primary outcome was treatment success (cessation of bleeding). Secondary outcomes included mortality, complications, and length of hospital stay. Results: Nine studies (n=1145 patients) were included. BAE was the most common intervention (7 studies), followed by bronchoscopic interventions (4 studies) and surgery (3 studies). Pooled analysis showed that BAE had a higher success rate compared to bronchoscopic interventions (OR 2.15, 95% CI 1.32-3.51, p=0.002) and surgery (OR 1.88, 95% CI 1.15-3.08, p=0.01). BAE was associated with a lower mortality rate compared to surgery (OR 0.43, 95% CI 0.21-0.88, p=0.02) but not bronchoscopic interventions (OR 0.78, 95% CI 0.45-1.35, p=0.37). Complication rates were similar across all interventions. Conclusion: BAE appears to be the most effective urgent interventional approach for massive hemoptysis, with a higher success rate and lower mortality compared to surgery. Bronchoscopic interventions may be considered in selected cases. Further research is needed to compare different BAE techniques and optimize patient selection.
Thermally Oxidized Cooking Palm Oil-Induced Histopathological Alterations in Brain, Heart, Liver, and Kidney: A Systematic Review of Lipid Peroxidation and Inflammatory Mechanisms Nimas Ayu Nirwanti; Ahmad Aulia Jusuf
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1273

Abstract

Background: Repeated heating of cooking palm oils at high temperatures generates various toxic compounds, including lipid peroxidation products. These compounds are implicated in various diseases through oxidative stress and inflammation. This systematic review aims to evaluate the histopathological effects of thermally oxidized cooking oil (TOCO) consumption on the brain, heart, liver, and kidney, focusing on the roles of lipid peroxidation and inflammation. Methods: A systematic search was conducted in PubMed, Scopus, and Web of Science databases using predefined keywords and inclusion/exclusion criteria. Studies published between 2013 and 2024 investigating the histopathological effects of TOCO on the specified organs were included. Data on histopathological changes, markers of lipid peroxidation (malondialdehyde [MDA], 4-hydroxynonenal [4-HNE]), and inflammatory markers (TNF-α, IL-1β, IL-6) were extracted. Results: Seven studies met the inclusion criteria. The data revealed consistent histopathological changes across all four organs. In the brain, neuronal degeneration, astrogliosis, and microglial activation were observed. The heart exhibited cardiomyocyte hypertrophy, fibrosis, and inflammatory cell infiltration. The liver showed hepatocyte necrosis, steatosis, and inflammation. The kidneys presented with tubular necrosis, glomerular damage, and interstitial fibrosis. Elevated levels of MDA and 4-HNE were consistently reported in all affected tissues, along with increased expression of TNF-α, IL-1β, and IL-6. Conclusion: Consumption of TOCO induces significant histopathological damage in the brain, heart, liver, and kidney. The observed damage is strongly associated with increased lipid peroxidation and inflammatory responses. These findings highlight the potential health risks associated with consuming repeatedly heated cooking oils and underscore the need for public health awareness and strategies to mitigate these risks.
Continuous Positive Airway Pressure (CPAP) versus Non-Invasive Ventilation (NIV) in Obesity Hypoventilation Syndrome: A Meta-Analysis Meliza Wahyuni; Yessy Susanty Sabri; Fenty Anggrainy
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1274

Abstract

Background: Obesity hypoventilation syndrome (OHS) is a serious respiratory condition characterized by obesity, sleep-disordered breathing, and daytime hypercapnia. Both continuous positive airway pressure (CPAP) and non-invasive ventilation (NIV) are commonly used to treat OHS, but their comparative effectiveness remains unclear. This meta-analysis aimed to compare the efficacy of CPAP versus NIV in improving gas exchange, sleep quality, and quality of life in patients with OHS. Methods: A systematic search of electronic databases (PubMed, Scopus, Web of Science) was conducted from 2013 to 2024 to identify randomized controlled trials (RCTs) comparing CPAP and NIV in adults with OHS. The primary outcomes were changes in daytime arterial carbon dioxide (PaCO2) and apnea-hypopnea index (AHI). Secondary outcomes included changes in daytime arterial oxygen (PaO2), sleep efficiency, and quality of life measures. Data were pooled using a random-effects model, and the standardized mean difference (SMD) with 95% confidence intervals (CI) was calculated. Results: Seven RCTs with a total of 584 participants were included in the meta-analysis. Compared to CPAP, NIV was associated with a significantly greater reduction in PaCO2 (SMD -0.45; 95% CI -0.88 to -0.02; p=0.04) and AHI (SMD -0.61; 95% CI -1.17 to -0.05; p=0.03). NIV also showed a trend towards greater improvement in PaO2, although this was not statistically significant (SMD 0.32; 95% CI -0.06 to 0.70; p=0.10). No significant differences were observed between CPAP and NIV in sleep efficiency or quality of life measures. Conclusion: This meta-analysis suggests that NIV is more effective than CPAP in improving gas exchange and reducing apnea-hypopnea events in patients with OHS. While both treatments appear to be well-tolerated, NIV may be the preferred initial treatment option for OHS, especially in patients with significant hypercapnia.
Pregnancy-Triggered Severe Lupus Nephritis with Pleural Effusion: A Case Report Zaki Mahmudi Dasril; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1275

Abstract

Background: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), characterized by kidney inflammation. Pregnancy can trigger or exacerbate LN due to hormonal shifts and altered immune responses. This case highlights the challenges in diagnosing and managing pregnancy-associated LN. Case presentation: A 27-year-old woman presented with anasarca, malar rash, shortness of breath, and foamy urine during her first pregnancy. She had a history of SLE with previous symptoms limited to skin and joint involvement. Investigations revealed nephrotic-range proteinuria, hematuria, elevated creatinine, and positive anti-nuclear antibodies (ANA). Renal biopsy confirmed Class IV lupus nephritis. She was diagnosed with pregnancy-triggered severe LN with nephrotic syndrome, pleural effusion, and a hypercoagulable state. Treatment included high-dose corticosteroids and mycophenolate mofetil, with close monitoring of both maternal and fetal health. Conclusion: This case underscores the importance of recognizing and promptly managing LN in pregnancy. Early diagnosis, multidisciplinary care, and individualized treatment are crucial to optimize maternal and fetal outcomes.
Chondroprotective Potential of Oleocanthal and Hydroxytyrosol from Extra Virgin Olive Oil: A Meta-Analysis Muhammad Addien Prima Nanda; Muhammad Reagen
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1276

Abstract

Background: Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage degradation, inflammation, and pain. Oleocanthal and hydroxytyrosol, two potent anti-inflammatory and antioxidant polyphenols found in extra virgin olive oil (EVOO), have shown promising chondroprotective effects in preclinical studies. This meta-analysis aimed to evaluate the efficacy of oleocanthal and hydroxytyrosol in preventing cartilage degradation and ameliorating OA symptoms. Methods: A systematic search of electronic databases (PubMed, Scopus, and Web of Science) was conducted to identify relevant studies published between 2013 and 2024. Randomized controlled trials (RCTs) and preclinical studies investigating the effects of oleocanthal or hydroxytyrosol on OA were included. The primary outcome was cartilage degradation, assessed by imaging or histological scores. Secondary outcomes included pain and inflammation. Results: Nine studies (4 RCTs and 5 preclinical studies) met the inclusion criteria. The RCTs included a total of 315 participants with knee OA. The interventions consisted of oral administration of oleocanthal or hydroxytyrosol at various doses and durations. The preclinical studies used different in vivo animal models. Pooled analysis of the RCTs showed that oleocanthal or hydroxytyrosol significantly reduced cartilage degradation compared to control (SMD = -0.85, 95%CI -1.20 to -0.50, p < 0.001). In the preclinical studies, oleocanthal and hydroxytyrosol also significantly reduced cartilage degradation scores (SMD = -1.10, 95%CI -1.50 to -0.70, p < 0.001). Pooled analysis of pain outcomes showed a significant reduction with oleocanthal or hydroxytyrosol compared to control (Preclinical: SMD = -0.60, 95%CI -0.90 to -0.30, p < 0.001; RCTs: SMD=-1.20, 95%CI-1.60 to -0.80, p < 0.001). Oleocanthal and hydroxytyrosol significantly reduced inflammatory markers (Preclinical: SMD = -0.85, 95%CI-1.15 to -0.55, p < 0.001; RCTs: SMD= -1.50, 95%CI-1.90 to -1.10, p < 0.001). Conclusion: This meta-analysis provides evidence for the chondroprotective potential of oleocanthal and hydroxytyrosol from EVOO. These polyphenols may offer a promising therapeutic strategy for preventing cartilage degradation, reducing pain, and improving OA symptoms. Further large-scale RCTs are warranted to confirm these findings and establish optimal dosage and treatment duration.
The Efficacy of Antimalarial Therapy in the Treatment of Pulmonary Malaria: A Meta-Analysis Nalia Maharani AP; Dewi Wahyu Fitrina; Fenty Anggrainy
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1277

Abstract

Background: Pulmonary malaria, a severe form of malaria that affects the lungs, is associated with high mortality rates. Antimalarial therapy is the cornerstone of treatment, but the optimal regimen remains a subject of debate. This meta-analysis aimed to evaluate the efficacy of different antimalarial therapies in the treatment of pulmonary malaria. Methods: A systematic search of electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) was conducted to identify randomized controlled trials (RCTs) comparing different antimalarial therapies for pulmonary malaria. The primary outcome was mortality. Secondary outcomes included parasite clearance time, respiratory distress resolution, and length of hospital stay. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Results: Seven RCTs met the inclusion criteria, enrolling a total of 1,245 patients with pulmonary malaria. The studies compared various antimalarial regimens, including artemisinin-based combination therapy (ACT), quinine, and artesunate. The meta-analysis showed that ACT was associated with a significantly lower risk of mortality compared to quinine (RR 0.67, 95% CI 0.52-0.86, p = 0.002). There was no significant difference in mortality between ACT and artesunate (RR 0.92, 95% CI 0.75-1.13, p = 0.43). ACT was also associated with a faster parasite clearance time and quicker resolution of respiratory distress compared to quinine. Conclusion: ACT is an effective treatment for pulmonary malaria, associated with reduced mortality and improved clinical outcomes compared to quinine. There was no significant difference in efficacy between ACT and artesunate. These findings support the use of ACT as the preferred antimalarial regimen for patients with pulmonary malaria.
Platelet-to-Lymphocyte Ratio in Pediatric Dengue Patients: A Key Indicator of Disease Severity Silma Farraha; Husni; Deswita Sari; Rikarni; Zelly Dia; Dwi Yulia
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1278

Abstract

Background: Dengue infection remains a significant health concern in Indonesia, with a high mortality rate. Early identification and prediction of severe dengue are crucial for effective management and mortality reduction. The platelet-to-lymphocyte ratio (PLR) has emerged as a potential biomarker for assessing dengue severity due to its association with inflammatory responses. Methods: This descriptive study included 48 pediatric patients diagnosed with dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) at Dr. M. Djamil General Hospital Padang between March and August 2024. Patients were included if they were aged 0-18 years, had a confirmed diagnosis of DHF or DSS, and underwent complete blood count and serological testing for dengue. Patients with chronic diseases or other comorbidities were excluded. Complete blood counts were performed using flow cytometry, and PLR was calculated by dividing the platelet count by the absolute lymphocyte count. Clinical data were obtained from medical records. Results: The majority of patients were aged 6-18 years (68.8%), with 20 (41.7%) presenting with DHF and 28 (58.3%) with DSS. The median platelet count was lower in DSS patients (26,000/mm3) compared to DHF patients (35,500/mm3). The median PLR was also significantly lower in DSS patients (8.95) compared to DHF patients (15.61). A PLR value <20 was more frequently observed in DSS patients (89.3%) than in DHF patients (75%). Conclusion: A lower PLR value was associated with more severe clinical manifestations of dengue infection, particularly DSS. PLR can serve as a valuable biomarker for assessing dengue severity, utilizing readily available and cost-effective complete blood count results.
Monocyte-to-HDL Cholesterol Ratio Predicts 30-Day Mortality in ST-Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention Kurniawan; Yaswir, Rismawati; Deswita Sari; Zelly Dia Rofinda; Dwi Yulia; Syofiati
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1279

Abstract

Background: ST-elevation myocardial infarction (STEMI) is a leading cause of mortality worldwide. Despite advancements in treatment, especially with primary percutaneous coronary intervention (pPCI), 30-day mortality rates remain significant. The monocyte-to-high-density lipoprotein cholesterol ratio (MHR) has emerged as a potential predictor of mortality in STEMI patients, reflecting the balance between inflammation and anti-atherosclerotic processes in atherosclerotic plaques. This study aimed to evaluate the association between MHR and 30-day mortality in STEMI patients undergoing pPCI. Methods: This prospective observational study included 55 STEMI patients treated with pPCI at Dr. M. Djamil General Hospital in Padang, Indonesia, between January and July 2024. Patients were included if they were ≥18 years old, undergoing their first pPCI, and had blood tests done within 24 hours of admission. Patients with prior revascularization, acute/chronic infections, malignancies, autoimmune diseases, or on lipid-lowering therapy were excluded. Blood samples were collected within 24 hours of admission. Monocyte counts were measured using flow cytometry, and HDL cholesterol levels were determined using a homogeneous enzymatic colorimetric method. The MHR was calculated by dividing the monocyte count by the HDL cholesterol level. The primary outcome was 30-day mortality, assessed through hospital records and telephone follow-up. Statistical analysis included chi square, t-tests, and Mann-Whitney U tests. Results: The mean age of the study participants was 59.5 (±11.4) years, with 81.8% being male. The mean monocyte count and MHR were 968 (±212)/mm3 and 28.3 (±6.06), respectively. The median HDL cholesterol level was 33.4 (27-49) mg/dL. Both monocyte count and MHR were significantly higher in patients who died within 30 days compared to those who survived (p<0.001). Conclusion: The MHR is an independent predictor of 30-day mortality in STEMI patients undergoing pPCI. This readily available and cost-effective biomarker may aid in risk stratification and guide treatment strategies for this high-risk population.
Mean Platelet Volume and Immature Platelet Fraction as Biomarkers in Differentiating Early-Onset and Late-Onset Neonatal Sepsis Rahmi Dina Indra; Rikarni; Desiekawati; Zelly Dia Rofinda; Dwi Yulia; Elfira Yusri
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1280

Abstract

Background: Neonatal sepsis is a significant contributor to infant mortality, with millions of cases occurring globally each year. It is classified into early-onset neonatal sepsis (EONS), occurring within the first 72 hours of life, and late-onset neonatal sepsis (LONS), occurring after 72 hours. Thrombocytopenia is a common finding in neonatal sepsis, and the degree of thrombocytopenia has been associated with the severity of the disease. Mean platelet volume (MPV) and immature platelet fraction (IPF) are markers of platelet size and immaturity, respectively, and may provide insights into the pathophysiology of sepsis and aid in its diagnosis. Methods: This cross-sectional analytical study was conducted at Dr. M. Djamil General Hospital in Padang, Indonesia, from June to September 2024. The study included 41 neonates diagnosed with sepsis. Complete blood counts were performed using an automated hematology analyzer to determine MPV, IPF, and platelet count. Neonatal sepsis was classified as EONS (within the first 7 days of life) or LONS (from day 8 to 28). Data were analyzed using descriptive statistics and the unpaired t-test. Results: The mean age of the neonates was 11.6 days. There were 19 neonates with EONS and 22 with LONS. The mean MPV was significantly higher in the LONS group (11.7 fL) compared to the EONS group (10.2 fL) (p=0.001). Similarly, the mean IPF was significantly higher in the LONS group (10.9%) compared to the EONS group (7.7%) (p=0.001). There was no significant difference in platelet count between the two groups. Conclusion: MPV and IPF were significantly higher in neonates with LONS compared to those with EONS, suggesting that these parameters may be useful biomarkers for differentiating between the two conditions. Further research with a larger sample size and longitudinal follow-up is needed to confirm these findings and to assess the potential clinical utility of MPV and IPF in the management of neonatal sepsis.
The Triglyceride-Glucose Index: A Potential Simple Screening Tool for Insulin Resistance in Young Adults Kenny; Efrida; Elfira Yusri; Rismawati Yaswir; Husni; Syofiati
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i5.1281

Abstract

Background: Insulin resistance is a key factor in the development of metabolic diseases, which are increasingly prevalent in young adults. Early detection is crucial for timely intervention. The triglyceride-glucose (TyG) index, calculated from fasting triglyceride and glucose levels, has emerged as a potential alternative to the more complex homeostasis model assessment of insulin resistance (HOMA-IR). This study aimed to evaluate the agreement between the TyG index and HOMA-IR in detecting insulin resistance in young adults. Methods: A cross-sectional study was conducted on 102 non-diabetic young adults (aged 18-22 years). Fasting blood samples were collected to measure triglyceride, glucose, and insulin levels. The agreement between the TyG index and HOMA-IR was assessed using the Kappa coefficient. Results: The median age of the participants was 20 years, with 65.7% being female. The prevalence of insulin resistance was 79.4% based on the TyG index (cut-off value of 4.25) and 43.1% based on HOMA-IR (cut-off value of 2.2). The agreement between the two indices was slight (Kappa = 0.155, p = 0.001). Conclusion: The TyG index showed a higher prevalence of insulin resistance compared to HOMA-IR in this population. However, the agreement between the two indices was low. Further research is needed to validate the TyG index as a screening tool for insulin resistance in young adults.

Page 94 of 117 | Total Record : 1165


Filter by Year

2017 2025


Filter By Issues
All Issue Vol. 9 No. 12 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 11 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 10 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 10 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 10 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 9 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 8 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 7 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 6 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 5 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 4 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 3 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 9 No. 1 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 12 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 11 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 10 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 8 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 7 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 6 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 5 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 4 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 3 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 2 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 8 No. 1 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 12 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 11 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 10 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 18 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 17 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 9 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 8 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 7 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 6 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 5 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 4 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 15 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 14 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 13 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 12 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 11 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 10 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 9 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 8 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 7 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 6 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 5 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 4 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 3 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 2 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 6 No. 1 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 12 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 11 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 10 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 9 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 8 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 7 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 6 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 5 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 4 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 3 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 2 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 5 No. 1 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research Vol. 4 No. 4 (2020): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 4 No. 3 (2020): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 4 No. 2 (2020): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 4 No. 1 (2020): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 3 No. 4 (2019): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 3 No. 3 (2019): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 3 No. 2 (2019): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 3 No. 1 (2019): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 2 No. 4 (2018): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 2 No. 3 (2018): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 2 No. 2 (2018): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 2 No. 1 (2018): Bioscientia Medicina: Journal of Biomedicine and Translational Research Vol. 1 No. 1 (2017): Bioscientia Medicina: Journal of Biomedicine and Translational Research More Issue